125 related articles for article (PubMed ID: 9858214)
1. In-vivo immune responses to idiotypic VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkin's lymphoma.
Wen YJ; Lim SH
Br J Haematol; 1998 Dec; 103(3):663-8. PubMed ID: 9858214
[TBL] [Abstract][Full Text] [Related]
2. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
3. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma.
Wen YJ; Lim SH
Eur J Immunol; 1997 Apr; 27(4):1043-7. PubMed ID: 9130662
[TBL] [Abstract][Full Text] [Related]
4. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma.
Wen YJ; Ling M; Lim SH
Br J Haematol; 1998 Mar; 100(3):464-8. PubMed ID: 9504627
[TBL] [Abstract][Full Text] [Related]
6. Different properties of T-cell epitopes within complementarity-determining regions 1 and 2 of idiotypic VH in B-lymphoma.
Wen YJ; Lim SH
Scand J Immunol; 1999 Sep; 50(3):296-301. PubMed ID: 10447939
[TBL] [Abstract][Full Text] [Related]
7. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
[TBL] [Abstract][Full Text] [Related]
8. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
[TBL] [Abstract][Full Text] [Related]
9. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination.
Zang YC; Hong J; Rivera VM; Killian J; Zhang JZ
J Immunol; 2000 Apr; 164(8):4011-7. PubMed ID: 10754292
[TBL] [Abstract][Full Text] [Related]
10. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
Lim SH; Bailey-Wood R
Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
[TBL] [Abstract][Full Text] [Related]
11. Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia.
Rezvany MR; Jeddi-Tehrani M; Rabbani H; Rudén U; Hammarström L; Osterborg A; Wigzell H; Mellstedt H
Br J Haematol; 2000 Oct; 111(1):230-8. PubMed ID: 11091206
[TBL] [Abstract][Full Text] [Related]
12. Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells.
Zang YC; Hong J; Rivera VM; Killian J; Zhang JZ
Int Immunol; 2003 Sep; 15(9):1073-80. PubMed ID: 12917259
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model.
Rinaldi M; Fioretti D; Iurescia S; Signori E; Pierimarchi P; Seripa D; Tonon G; Fazio VM
Biochem Biophys Res Commun; 2008 May; 370(2):279-84. PubMed ID: 18364239
[TBL] [Abstract][Full Text] [Related]
14. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
15. A genetic approach to idiotypic vaccination for B cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
[TBL] [Abstract][Full Text] [Related]
16. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
17. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H
Int J Cancer; 2001 Feb; 91(4):516-22. PubMed ID: 11251975
[TBL] [Abstract][Full Text] [Related]
18. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination.
Hong J; Zang YC; Tejada-Simon MV; Li S; Rivera VM; Killian J; Zhang JZ
J Immunol; 2000 Dec; 165(12):6858-64. PubMed ID: 11120809
[TBL] [Abstract][Full Text] [Related]
19. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.
Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK
Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458
[TBL] [Abstract][Full Text] [Related]
20. Derangement of the T-cell repertoire in patients with B-cell non-Hodgkin's lymphoma.
Fozza C; Corda G; Virdis P; Contini S; Barraqueddu F; Galleu A; Isoni A; Cossu A; Dore F; Careddu MG; Bonfigli S; Giannico B; Longinotti M
Eur J Haematol; 2015 Apr; 94(4):298-309. PubMed ID: 25040028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
